ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stake Boosted by Pacer Advisors Inc.

Pacer Advisors Inc. grew its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 23,259.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 568,343 shares of the specialty pharmaceutical company’s stock after purchasing an additional 565,910 shares during the quarter. Pacer Advisors Inc.’s holdings in ANI Pharmaceuticals were worth $33,907,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Sequoia Financial Advisors LLC bought a new position in shares of ANI Pharmaceuticals during the second quarter valued at approximately $600,000. Global Alpha Capital Management Ltd. grew its holdings in shares of ANI Pharmaceuticals by 1.8% during the third quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock valued at $32,005,000 after purchasing an additional 9,500 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new position in shares of ANI Pharmaceuticals during the second quarter valued at approximately $228,000. Boston Partners bought a new position in shares of ANI Pharmaceuticals during the first quarter valued at approximately $606,000. Finally, Thompson Siegel & Walmsley LLC grew its holdings in ANI Pharmaceuticals by 17.6% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company’s stock worth $13,731,000 after buying an additional 34,416 shares in the last quarter. 76.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on ANIP shares. StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Truist Financial increased their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a report on Tuesday, October 22nd. Raymond James increased their price objective on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a report on Wednesday, September 18th. HC Wainwright reissued a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Finally, Piper Sandler started coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $77.33.

ANI Pharmaceuticals Stock Performance

ANIP opened at $56.91 on Friday. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -103.47 and a beta of 0.71. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. ANI Pharmaceuticals, Inc. has a 1-year low of $48.20 and a 1-year high of $70.81. The business has a 50 day moving average price of $58.34 and a two-hundred day moving average price of $61.03.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. The firm had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm’s revenue for the quarter was up 12.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.05 earnings per share. Research analysts predict that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.